Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2018

View Archived Issues

Phase II results on regorafenib in patients with metastatic osteosarcoma

ChlaDUB1, a Chlamydia effector protein with dual deubiquitination and acetylation activities

Hantavirus cell entry occurs by interaction between protocadherin-1 and viral surface glycoproteins

Mice, MRI and malaria

Claudin changes lead to leaky BBB after stroke

Antibody improves animal ALS symptoms

Patient dosing initiated in phase I study of BAT-4306F

Seres Therapeutics initiates phase II study of SER-287 in ulcerative colitis

FF-10501-01 demonstrates evidence of efficacy in patients with AML and MDS

PARP14 identified as a novel therapeutic target in STAT6-mutant follicular lymphoma

Calithera Biosciences presents early phase II results for CB-839 plus paclitaxel in advanced TNBC

Tychan initiates first-in-human study of TY-014 for Yellow fever

First clinical data presented for TK-006 in breast cancer patients with bone metastasis

E-2814 to begin phase I trials early next year for Alzheimer's disease

FDA places partial clinical hold on phase I studies of MGD-009

Bristol-Myers Squibb and Vedanta collaborate to study Opdivo with VE-800 in advanced cancers

Arctic Pharma discovers lactate dehydrogenase A inhibitors

Sigma1R ligands described by Integrative Research Laboratories Sweden

New P2X4 receptor antagonists synthesized at Bayer

Idorsia Pharmaceuticals patents prostanoid EP2 and/or EP4 receptor antagonists

Taizhou Huayuan Medicinal Tech describes deuterated anxiolytic compounds

C4X Discovery Holdings and e-therapeutics collaboration meets success

Phase I/II trial data of VAL-201 show dose-dependent response in PSA reduction

Avacta enters development alliance with LG Chem Life Sciences

Affimed outlines plans for clinical development and registrational plans for AFM-13

e-therapeutics enters type 2 diabetes research collaboration with Novo Nordisk

Researchers develop new murine model of neurodegeneration

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 12, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...